TNYA

Tenaya Therapeutics, Inc.

8 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 29

Removal of annual caps on equity incentive plan increases long-term dilution risk.

dilution risk

70%

neutralMay 29

Election of Class II directors completed at the annual meeting.

management change

40%

bullishMay 6

Operating expenses decreased by 26% year-over-year due to workforce optimization.

margin expansion

70%

bullishMay 6

Entered a strategic research collaboration with Alnylam Pharmaceuticals.

acquisition

60%

bearishMay 6

Significant warrant overhang and a history of equity offerings to fund operations.

dilution risk

80%

bearishMay 6

Previous clinical hold on MyPEAK-1 trial by the FDA in November 2025.

regulatory action

50%

bullishMay 6

Operating expenses decreased by 26% year-over-year due to workforce optimization.

margin expansion

70%

bullishMay 6

Entered a strategic research collaboration with Alnylam Pharmaceuticals.

acquisition

60%

bearishMay 6

Significant warrant overhang and a history of equity offerings to fund operations.

dilution risk

80%

bearishMay 6

Previous clinical hold on MyPEAK-1 trial by the FDA in November 2025.

regulatory action

50%

bullishMay 6

Operating expenses decreased by 26% year-over-year due to workforce optimization.

margin expansion

70%

bullishMay 6

Entered a strategic research collaboration with Alnylam Pharmaceuticals.

acquisition

60%

bearishMay 6

Significant warrant overhang and a history of equity offerings to fund operations.

dilution risk

80%

bearishMay 6

Previous clinical hold on MyPEAK-1 trial by the FDA in November 2025.

regulatory action

50%

bullishMay 6

Operating expenses decreased by 26% year-over-year due to workforce optimization.

margin expansion

70%

bullishMay 6

Entered a strategic research collaboration with Alnylam Pharmaceuticals.

acquisition

60%

bearishMay 6

Significant warrant overhang and a history of equity offerings to fund operations.

dilution risk

80%

bearishMay 6

Previous clinical hold on MyPEAK-1 trial by the FDA in November 2025.

regulatory action

50%

bullishMay 6

Operating expenses decreased by 26% year-over-year due to workforce optimization.

margin expansion

70%

bullishMay 6

Entered a strategic research collaboration with Alnylam Pharmaceuticals.

acquisition

60%

bearishMay 6

Significant warrant overhang and a history of equity offerings to fund operations.

dilution risk

80%

bearishMay 6

Previous clinical hold on MyPEAK-1 trial by the FDA in November 2025.

regulatory action

50%

bullishMay 6

Operating expenses decreased by 26% year-over-year due to workforce optimization.

margin expansion

70%

bullishMay 6

Entered a strategic research collaboration with Alnylam Pharmaceuticals.

acquisition

60%

bearishMay 6

Significant warrant overhang and a history of equity offerings to fund operations.

dilution risk

80%

bearishMay 6

Previous clinical hold on MyPEAK-1 trial by the FDA in November 2025.

regulatory action

50%

bullishMay 6

Operating expenses decreased by 26% year-over-year due to workforce optimization.

margin expansion

70%

bullishMay 6

Entered a strategic research collaboration with Alnylam Pharmaceuticals.

acquisition

60%

bearishMay 6

Significant warrant overhang and a history of equity offerings to fund operations.

dilution risk

80%

bearishMay 6

Previous clinical hold on MyPEAK-1 trial by the FDA in November 2025.

regulatory action

50%

Filing History

8-KMay 29, 2026

Tenaya Therapeutics' 8-K filing marks a pivotal shift in its corporate governance and compensation strategy. While the approval of the amended 2021 Equity Incentive Plan provides the company with the flexibility to attract world-class talent, it simultaneously introduces a more aggressive dilution profile. The tension between the need for human capital and the protection of shareholder equity is evident in the voting split, where a substantial minority opposed the measure. Ultimately, the impact of this filing depends on whether the expanded equity pool translates into tangible clinical milestones or simply serves as a mechanism to manage a liquidity crunch. Investors must now weigh the potential for accelerated growth against the risk of a shrinking per-share ownership stake.

10-QMay 6, 2026

Tenaya Therapeutics finds itself at a critical juncture, attempting to balance aggressive cost-cutting with the high-stakes demands of gene therapy development. The Q1 2026 filing reveals a company that has successfully lowered its burn rate and secured a prestigious partner in Alnylam, but remains fundamentally a high-risk, pre-revenue entity. The tension between the 'lean' narrative and the reality of a dwindling cash pile creates a volatile setup for investors. The upcoming second quarter of 2026 serves as the definitive pivot point. If Tenaya can produce robust, validated data from its lead programs and maintain its partnership with Alnylam, the current valuation may be seen as a discounted entry into a curative heart-disease platform. However, any delay in data readouts or a failure to secure additional non-dilutive funding will likely force a distressed equity raise, given the existing warrant overhang and loan covenants. Ultimately, the impact of this filing is a shift in the investment lens from pure discovery to execution. The market is no longer pricing in the 'possibility' of the technology, but rather the 'probability' of regulatory alignment and financial survival. Tenaya has bought itself time, but the window for a successful transition to late-stage development is narrow and fraught with single-point-of-failure risks.